Would you consider using endocrine therapy, pembrolizumab, capecitabine, or CDK 4/6 inhibitor?
Masuda et al. NEJM 2017
If so, how do you sequence it with adjuvant radiotherapy?
Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?